Sanofi Reports Strong Q1 2025 Performance

Sanofi ( (SNYNF) ) has released its Q1 earnings. Here is a breakdown of the information Sanofi presented to its investors.

Sanofi, a global healthcare leader in the pharmaceutical industry, has reported a robust first quarter in 2025, showcasing significant growth in sales and earnings. The company, known for its innovative medicines and vaccines, has confirmed its guidance for the year, reflecting confidence in its strategic direction.

Sanofi’s Q1 2025 earnings report highlights a 9.7% increase in sales at constant exchange rates, with business earnings per share rising to €1.79, marking a 15.7% increase. Key drivers of this growth include a 43.8% surge in pharma launches, notably led by ALTUVIIIO, and a 20.3% increase in Dupixent sales. Vaccine sales also saw an 11.4% rise, driven by the favorable phasing of Beyfortus.

The company achieved six regulatory approvals across its pipeline, enhancing its portfolio in immunology, rare diseases, and oncology. Sanofi’s sustainability strategy has been updated to focus on healthcare access, environmental impact, and resilience, aligning 70% of its portfolio with diseases affected by climate challenges.

Looking ahead, Sanofi maintains its guidance for 2025, anticipating mid-to-high single-digit sales growth and a strong rebound in business EPS. The company is also progressing with its €5 billion share buyback program, having completed 72% of it by the end of Q1 2025.